Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, Korea.
Radiology. 2013 May;267(2):396-404. doi: 10.1148/radiol.12120361. Epub 2013 Jan 11.
To investigate the efficacy of an IN-1233-eluting covered stent in preventing tissue hyperplasia in a rabbit esophageal model.
The local animal research committee approved all experiments. Esophageal stents were placed in 40 male New Zealand rabbits (weight range, 2.8-3.2 kg). The drug group (D) received IN-1233-eluting covered stents (n = 20); the control group (C) received polyurethane-covered stents (n = 20). Drug loading of IN-1233-eluting covered stent was 10%. Four study groups were formed: C and D animals sacrificed at 4 (D4, C4) and 8 (D8, C8) weeks after stent placement (n = 10). Esophagography was used to assess the percentage of diameter stenosis. Histologic findings of the drug and control stents were compared. The Mann-Whitney U test was used to evaluate differences.
The mean percentage ± standard deviation of diameter stenosis was significantly lower in D groups than in C groups at both 4 (C4 = 36.15% ± 12.63, D4 = 7.83% ± 8.12 [P < .001]) and 8 (C8 = 50.21% ± 20.43, D8 = 27.78% ± 14.40 [P = .019]) weeks. Percentage of granulation tissue area (C4 = 33.07% ± 19.11, D4 = 21.59% ± 18.22 [P = .028]; C8 = 44.70% ± 21.71, D8 = 31.97% ± 22.54 [P = .131]), number of epithelial layers (C4 = 4.77 ± 1.55, D4 = 3.37 ± 1.73 [P = .002]; C8 = 5.50 ± 1.38, D8 = 4.50 ± 1.63 [P = .057]), and thickness of submucosal fibrosis (C4 = 2.42 mm ± 1.08, D4 = 1.62 mm ± 0.77 [P = .006]; C8 = 2.89 mm ± 1.00, D8 = 2.07 mm ± 0.71 [P = .007]) were lower in D than in C groups. Inflammatory cell infiltration was significantly higher in D than in C groups (C4 = 2.63 ± 0.81, D4 = 3.33 ± 1.09 [P = .032]; C8 = 2.20 ± 0.81, D8 = 3.00 ± 0.95 [P = .012]).
The use of an IN-1233-eluting covered stents decreased tissue hyperplasia secondary to stent placement in a rabbit esophageal model.
研究 IN-1233 洗脱覆膜支架预防兔食管模型组织增生的疗效。
当地动物研究委员会批准了所有实验。将食管支架置于 40 只雄性新西兰兔(体重 2.8-3.2kg)体内。药物组(D 组)接受 IN-1233 洗脱覆膜支架(n=20);对照组(C 组)接受聚氨酯覆膜支架(n=20)。IN-1233 洗脱覆膜支架的药物载量为 10%。分为 4 个研究组:C 组和 D 组动物分别于支架置入后 4(D4、C4)和 8(D8、C8)周处死(n=10)。采用食管造影评估直径狭窄的百分比。比较药物和对照支架的组织学发现。采用 Mann-Whitney U 检验评估差异。
D 组的平均直径狭窄率显著低于 C 组,在 4 周(C4=36.15%±12.63,D4=7.83%±8.12[P<.001])和 8 周(C8=50.21%±20.43,D8=27.78%±14.40[P=0.019])时均如此。肉芽组织面积百分比(C4=33.07%±19.11,D4=21.59%±18.22[P=0.028];C8=44.70%±21.71,D8=31.97%±22.54[P=0.131])、上皮层数(C4=4.77±1.55,D4=3.37±1.73[P=0.002];C8=5.50±1.38,D8=4.50±1.63[P=0.057])和黏膜下纤维化厚度(C4=2.42mm±1.08,D4=1.62mm±0.77[P=0.006];C8=2.89mm±1.00,D8=2.07mm±0.71[P=0.007])在 D 组均低于 C 组。D 组的炎症细胞浸润显著高于 C 组(C4=2.63±0.81,D4=3.33±1.09[P=0.032];C8=2.20±0.81,D8=3.00±0.95[P=0.012])。
在兔食管模型中,使用 IN-1233 洗脱覆膜支架可减少支架置入后引起的组织增生。